BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions
Relapsed or Refractory Multiple MyelomaPatients With BRAFV600 E or BRAFV600K Mutation
Interventions
DRUG

Encorafenib

450 mg p.o. once daily. One cycle is defined as 28 days

DRUG

Binimetinib

45 mg p.o. twice daily. One cycle is defined as 28 days

Trial Locations (7)

48149

Universitätsklinikum Münster, Med. Klinik und Poliklinik A, Münster

D-50937

Universitätsklinikum Köln, Klinik I Innere Medizin, Cologne

01307

Mediz. Klinik und Poliklinik 1, Universitätsklinikum Dresden, Dresden

D-60590

Universitätsklinikum Frankfurt, Medizinische Klinik II, Frankfurt am Main

D-69120

University Hospital Heidelberg, Med. Klinik V, Heidelberg

D-72076

Universitätsklinikum Tübingen, Medizinische Klinik II, Tübingen

D-97080

Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Array BioPharma

INDUSTRY

collaborator

German Cancer Research Center

OTHER

collaborator

Coordinating Centre for Clinical Trials Heidelberg

UNKNOWN

collaborator

University Hospital Heidelberg

OTHER

lead

University of Heidelberg Medical Center

OTHER

NCT02834364 - BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) | Biotech Hunter | Biotech Hunter